Prostatic ductal adenocarcinoma showing Bcl-2 expression.
Prostatic ductal adenocarcinoma represents a rare histological variant of prostatic carcinoma with features of a papillary lesion at cystoscopy. There are conflicts regarding the existence, origin, staging, grading, treatment and clinical behavior of this tumor. The aim of the present study is to examine the expression of Bcl-2 and p53 in prostatic ductal adenocarcinoma and to evaluate its origin by analyzing prostate specific antigen, prostate specific acid phosphatase, cytokeratins, epithelial membrane antigen and carcinoembryonic antigen expressions. The results confirmed the expression of prostate specific antigen and prostate specific acid phosphatase in prostatic ductal adenocarcinoma. The demonstrated expression of Bcl-2 was predominant in the better-differentiated tumor. Bcl-2 expression appears not to be associated with neuroendocrine differentiation as assessed by chromogranin A reactivity. Thus, the first case of a prostatic ductal adenocarcinoma showing Bcl-2 expression is presented. The tumor was negative for p53.
Tulunay
Ozden
O
Department of Pathology, Medical School of Ankara University, Morfoloji Binasi, S1hhiye, Ankara 06100, Turkey. tulunay@medicine.ankara.edu.tr
Orhan
Diclehan
D
Baltaci
Sümer
S
Gögüş
Cagatay
C
Müftüoglu
Yusuf Z
YZ
D000135:Acid Phosphatase / Q000378:metabolism; D000368:Aged; D000369:Aged, 80 and over; D044584:Carcinoma, Ductal / Q000378:metabolism* / Q000473:pathology; D053379:Chromogranin A; D002864:Chromogranins / Q000378:metabolism; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000473:pathology; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism*; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism
D053379:Chromogranin A; D002864:Chromogranins; D019253:Proto-Oncogene Proteins c-bcl-2; D016159:Tumor Suppressor Protein p53; D000135:Acid Phosphatase; D017430:Prostate-Specific Antigen